Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
The U.S. is moving to further ease restrictions on blood donations from gay and bisexual men and other groups that typically face higher risks of HIV. → Read More
The U.S. is moving to further ease restrictions on blood donations from gay and bisexual men and other groups that typically face higher risks of HIV. → Read More
The U.S. is moving to further ease restrictions on blood donations from gay and bisexual men and other groups that face higher risks of HIV. → Read More
Gay and bisexual men in monogamous relationships could soon be able to donate blood for the first time in decades. → Read More
Supporters of abortion rights have filed separate lawsuits challenging abortion pill restrictions in North Carolina and West Virginia. → Read More
WASHINGTON (AP) — Supporters of abortion rights filed separate lawsuits Wednesday challenging two states’ abortion pill restrictions, the opening salvo in what’s expected to be a protracted legal battle over access to the medications. The lawsuits argue that limits on the drugs in North Carolina and West Virginia run afoul of the federal authority of […] → Read More
WASHINGTON (AP) — Supporters of abortion rights filed separate lawsuits Wednesday challenging two states’ abortion pill restrictions, the opening salvo in what’s expected to be a protracted legal battle over access to the medications. The lawsuits argue that limits on the drugs in North Carolina and West Virginia run afoul of the federal authority of […] → Read More
U.S. health officials want to make COVID-19 vaccinations more like the annual flu shot → Read More
U.S. health officials want to make COVID-19 vaccinations more like the annual flu shot. The Food and Drug Administration proposed a simplified approach so that most adults and children would get a once-a-year shot. → Read More
WASHINGTON (AP) — U.S. health officials want to make COVID-19 vaccinations more like the annual flu shot. The Food and Drug Administration on Monday proposed a simplified approach for future vaccinat... → Read More
U.S. health officials want to make COVID-19 vaccinations more like the annual flu shot. The Food and Drug Administration on Monday proposed a simplified approach so that most adults and children would get a once-a-year shot. Americans would no longer have to keep track of how many shots they’ve received or when. The proposal comes as boosters have become a hard sell. The FDA is asking a panel of… → Read More
This means Americans would no longer have to keep track of how many shots they’ve received or how long it’s been since their last booster. → Read More
The Food and Drug Administration on Monday proposed a simplified approach so that most adults and children would get a once-a-year shot against COVID-19. → Read More
Here are some things to know about the FDA's approval of lecanemab, to be sold under the brand name Leqembi. → Read More
It also has potential safety risks that doctors and patients will have to carefully weigh. → Read More
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease’s underlying biology. → Read More
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease’s underlying biology. → Read More
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease’s underlying biology. → Read More
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease’s underlying biology. → Read More
U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease. The Food and Drug Administration granted the approval Friday for patients in the early stages of Alzheimer's. It's the first drug that’s been convincingly shown to slow the decline in memory and thinking that define the disease. But the $26,500-a-year medication comes with downsides,… → Read More